Jan van de Winkel
Chief Executive Officer bei GENMAB A/S
Vermögen: 182 Mio $ am 31.03.2024
Profil
Dr. Jan G. J. van de Winkel ist ein unabhängiger Direktor bei Omega Alpha SPAC, ein Chairman-Supervisory Director bei Hookipa Biotech AG, ein Chairman bei HOOKIPA Pharma, Inc, ein President & Chief Executive Officer bei Genmab A/S, ein Professor an der Universität von Utrecht und ein Chairman-Supervisory Board bei Regenesance BV. Er ist Mitglied des Board of Directors bei Omega Alpha SPAC, LEO Pharma A/S und Celdara Medical LLC. Dr. van de Winkel war zuvor als Mitglied bei BTF Pty Ltd. beschäftigt, als Mitglied des Aufsichtsrates bei ISA Pharmaceuticals BV, als Vice President bei Medarex Europe BV und als Vice President & Scientific Director bei Medarex, Inc. Außerdem war er Vorstandsmitglied bei Forward Pharma A/S. Er erhielt seinen Bachelor-Abschluss von der Universität Utrecht, einen Master-Abschluss von der Universität Utrecht, einen Master-Abschluss von der Radboud Universität Nijmegen und einen Doktor-Abschluss von der Radboud Universität Nijmegen.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GENMAB A/S
0,91% | 14.02.2024 | 600 497 ( 0,91% ) | 182 Mio $ | 31.03.2024 |
HOOKIPA PHARMA, INC.
0,01% | 09.06.2023 | 9 153 ( 0,01% ) | 6 517 $ | 31.03.2024 |
Aktive Positionen von Jan van de Winkel
| Unternehmen | Position | Beginn |
|---|---|---|
| GENMAB A/S | Chief Executive Officer | 01.06.2010 |
| HOOKIPA PHARMA INC. | Chairman | 01.10.2017 |
| OMEGA ALPHA SPAC | Director/Board Member | 11.01.2021 |
| University of Utrecht | Corporate Officer/Principal | 01.01.1996 |
Regenesance BV
 Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | Chairman | - |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Director/Board Member | 01.01.2017 |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Chairman | 18.10.2017 |
Leo Pharma, Inc.
 Leo Pharma, Inc. Drugstore ChainsRetail Trade Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ. | Director/Board Member | 01.01.2017 |
Ehemalige bekannte Positionen von Jan van de Winkel
| Unternehmen | Position | Ende |
|---|---|---|
| FORWARD PHARMA A/S | Director/Board Member | 03.05.2017 |
| ░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░ ░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Jan van de Winkel
| University of Utrecht | Graduate Degree |
| Radboud University Nijmegen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GENMAB A/S | Health Technology |
| HOOKIPA PHARMA INC. | Health Technology |
| Private Unternehmen | 11 |
|---|---|
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
| Medarex Europe BV | |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
BTF Pty Ltd.
 BTF Pty Ltd. Miscellaneous Commercial ServicesCommercial Services BTF Pty Ltd. develops biological products. Its products include microorganism testing products such as BioBall, EasySeed, ColorSeed, EasyStain, and EasyPC. The company was founded Mark Gauci and Graham Vesey in March 1999 and is headquartered in North Ryde, Australia | Commercial Services |
ISA Pharmaceuticals BV
 ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |
Forward Pharma A/S
 Forward Pharma A/S Pharmaceuticals: MajorHealth Technology Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark. | Health Technology |
Leo Pharma, Inc.
Leo Pharma, Inc. Drugstore ChainsRetail Trade Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ. | Retail Trade |
Regenesance BV
Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | Retail Trade |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Health Technology |
Celdara Medical LLC
 Celdara Medical LLC BiotechnologyHealth Technology Celdara Medical LLC engages in development of early-stage medical inventions and discoveries. It builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical was founded in 2008 by Jake Reder and Michael W. Fanger and is headquartered in Lebanon, NH. | Health Technology |
Omega Alpha SPAC
 Omega Alpha SPAC Financial ConglomeratesFinance Omega Alpha SPAC is a blank check company. Its purposes effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Otello Stampacchia, Michelle Doig, Francesco Draetta and Vincent Ossipow on October 26, 2020 and is headquartered in Boston, MA. | Finance |
